{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:02:37Z","timestamp":1788386557741,"version":"build-2803163510"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To explore the correlations of botulinum toxin (BT) therapy with dysphagia, we wanted to study a group of cervical dystonia (CD) patients with optimised BT therapy during a prolonged period of time to record their dysphagia frequency, severity and duration, to study potential risk factors and try to avoid it by BT application with ultrasound guidance. BT therapy of 75 CD patients (23 males, 52 females, age 60\u2009\u00b1\u200912\u00a0years, BT total dose 303.5\u2009\u00b1\u2009101.5 uMU) was retrospectively analysed for 1\u00a0year. BT therapy was optimised prior to the observation period. Dysphagia was noticed by one fifth of the patients. In those patients, it only occurred in about one third of the injection series. It was never associated with a functional deficit and lasted several days to 2\u00a0weeks. It was not related to patient age or gender, BT total dose, BT dose in the sternocleidomastoid muscle, BT dose in the sternocleidomastoid and scalenii muscles, by BT therapy with bilateral sternocleidomastoid muscle injections or BT therapy with abobotulinumtoxinA. Ultrasound guidance was not able to prevent it. Further prospective studies will be necessary to study underlying dystonia associated swallowing abnormalities as a potentially predisposing factor.<\/jats:p>","DOI":"10.1007\/s00702-020-02220-z","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T19:02:20Z","timestamp":1593111740000},"page":"1161-1165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study"],"prefix":"10.1007","volume":"127","author":[{"given":"Anna","family":"Kutschenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Klietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejla","family":"Paracka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Kollewe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Schulte-Sutum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theda","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wegner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"1","key":"2220_CR1","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","volume":"92","author":"P Albrecht","year":"2019","unstructured":"Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, Bigalke H, Aktas O, Hartung HP, Hefter H (2019) High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 92(1):e48\u2013e54","journal-title":"Neurology"},{"issue":"9","key":"2220_CR2","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1177\/014107689208500906","volume":"85","author":"TJ Anderson","year":"1992","unstructured":"Anderson TJ, Rivest J, Stell R, Steiger MJ, Cohen H, Thompson PD, Mardsden CD (1992) Botulinum toxin treatment of spasmodic torticollis. J R Soc Med 85(9):524\u2013529","journal-title":"J R Soc Med"},{"issue":"8","key":"2220_CR3","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1136\/jnnp.53.8.640","volume":"53","author":"JD Blackie","year":"1990","unstructured":"Blackie JD, Lees AJ (1990) Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 53(8):640\u2013643","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"7","key":"2220_CR4","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1212\/WNL.42.7.1307","volume":"42","author":"CL Comella","year":"1992","unstructured":"Comella CL, Tanner CM, DeFoor-Hill L, Smith C (1992) Dysphagia after botulinum toxin injections for spasmodic torticollis: clinical and radiolgic findings. Neurology 42(7):1307\u201313310","journal-title":"Neurology"},{"issue":"1\u20132","key":"2220_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","volume":"308","author":"CL Comella","year":"2011","unstructured":"Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S, U.S. XEOMIN Cervical Dystonia Study Group (2011) Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN\u00ae, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci 308(1\u20132):103\u2013109","journal-title":"J Neurol Sci"},{"issue":"1","key":"2220_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00702-019-02109-6","volume":"127","author":"SC Drexel","year":"2020","unstructured":"Drexel SC, Klietz M, Kollewe K, Paracka L, Kutschenko A, Kopp B, Lange F, Wegner F, Dressler D (2020) Caregiver burden and health-related quality of life in idiopathic dystonia patients under botulinum toxin treatment: a cross-sectional study. J Neural Transm 127(1):61\u201370","journal-title":"J Neural Transm"},{"issue":"1","key":"2220_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40268-014-0077-1","volume":"15","author":"J Frevert","year":"2015","unstructured":"Frevert J (2015) Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 15(1):1\u20139","journal-title":"Drugs R D"},{"issue":"1","key":"2220_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","volume":"64","author":"W Poewe","year":"1998","unstructured":"Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Baumann AO, Ohly A, Oertel W, K\u00fcnig G (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double bling, placebo controlled, dose ranging study using Dysport. German Dystonia Study Group. J Neurol Neurosurg Psychiatry 64(1):13\u201317","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"2220_CR9","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"D Truong","year":"2010","unstructured":"Truong D, Brdodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S, Global Dysport Cervcal Dystonia Study Group (2010) Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16(5):316\u2013323","journal-title":"Parkinsonism Relat Disord"},{"key":"2220_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1586\/14737175.2014.936387","volume":"14","author":"U Walter","year":"2014","unstructured":"Walter U, Dressler D (2014) Ultrasound-guided botulinum toxin injections in neurology: technique, indications and future perspectives. Expert Rev Neurother 14:923\u2013936","journal-title":"Expert Rev Neurother"},{"issue":"12","key":"2220_CR11","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1007\/s00415-008-0031-7","volume":"255","author":"K Wohlfarth","year":"2008","unstructured":"Wohlfarth K, Schwandt I, Wegner F, J\u00fcrgens T, Gelbrich G, Wagner A, Bogdahn U, Schulte-Mattler W (2008) Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study. J Neurol 255(12):1932\u20131939","journal-title":"J Neurol"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-020-02220-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-020-02220-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T10:51:25Z","timestamp":1667127085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-020-02220-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,25]]},"references-count":11,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["2220"],"URL":"https:\/\/doi.org\/10.1007\/s00702-020-02220-z","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,25]]},"assertion":[{"value":"4 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DD received honoraria for services provided to Allergan, Ipsen, Merz, Lanzhou Institute of Biological Products, Medy-Tox, Revance, Desitin, Syntaxin, Abbvie, Medtronic, St Jude, Boston Scientific, Almirall, Bayer, Sun, Teva, UCB, IAB-Interdisciplinary Working Group for Movement Disorders. He is shareholder of Allergan and holds patents on botulinum toxin and botulinum toxin therapy. He provides professional consulting services to pharmaceutical companies and professional investment institutions on all aspects of botulinum toxin drugs. MK received honoraria for services provided to Novartis and has received research support for the German \u201cArbeitskreis Botulinumtoxin\u201d. KK received travel grants and\/or honoraria for lectures from Allergan, Biogen, Ipsen, Lilly, Merz, Novartis, Teva. AK, LP, ASS, TJ, FW have no conflict of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the local Ethics Committee of Hannover Medical School. All the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients gave written informed consent to the restrospective analysis of their digital BT therapy data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients gave written informed consent for the publication.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}